

International Symposium on Alternatives Assessment

Alternatives Assessment under REACH

Elke Van Asbroeck
Managing Director

DISCLAIMER: The information contained in this document is intended for guidance only and whilst the information is provided in utmost good faith and has been based on the best information currently available, it is to be relied upon at the user's own risk. No representations or warranties are made with regards to its completeness or accuracy and no liability will be accepted for damages of any nature whatsoever resulting from the use of or reliance on the information. This document is intellectual property of Apeiron-Team NV. This communication shall not be used or modified, unless written agreement by the management of Apeiron-Team NV.









Registration

Evaluation

Authorisation
& Restriction

Safe Use of Chemicals





= Substance of Very High Concern (REACH, art 57)

Carcinogenic cat 1A/1B


Mutagenic cat 1A/1B

Reprotoxic cat 1A/1B

Persistent, bioaccumulative and toxic

Very persistent and very bioaccumulative

“Equivalent concern” (e.g. endocrine disruptors, sensitizers)






Latest
Application
Date

Sunset
Date



Triggers for substitution



Source: **Impacts of REACH Authorisation (Nov 2017)**

EU Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs

https://ec.europa.eu/growth/content/commission-publishes-study-impacts-reach-authorisation_en

AUTHORISATION



Risk Management of 




1. Risks properly controlled
2. SVHCs progressively replaced




- Exposure is well controlled
- Minimization of emissions




- Past R&D efforts
- Opportunities to find suitable alternatives
- Development plan & timelines




Balance of impacts:
Do the benefits outweigh the risks?






Example: Protection from HIV



Fact: 23 million people HIV+
in Sub-Saharan Africa

HIV infections
= 450.000 girls age 15-24 /year







BUT - even if not a preferred alternative - the quickest and cheapest in case of refused authorisation.

Example: Batik Textiles









PERC although not a preferred alternative
(risk, technically, economically and availability),
the quickest and cheapest in case of refused authorisation

Switchable solvent = innovative potential alternative
Risk reduction and reduction of energy consumption
Development time estimated at 12 yrs



THIS IS WHERE
THE MAGIC HAPPENS



where Strategy, Science
and Efficiency meet

Apeiron



ir. Elke Van Asbroeck
Managing Director

Apeiron-Team nv
Berten Pilstraat 4
2640 Mortsel, Belgium
T. +32 (0)3 808 20 69
M. +32 (0)474 60 40 18
elke.vanasbroeck@apeiron-team.eu
www.apeiron-team.eu
BTW BE 0819.566.460